Rheumatologists Reviewed Scleroderma Lung Disease Guidelines

Experts examined updated treatment protocols for managing interstitial lung disease in systemic sclerosis patients.

Updated on Oct. 5, 2026 in Asthma

A modern, empty clinical hospital hallway with soft, diffuse lighting and clean architectural lines. — Rheumatologists have reviewed updated treatment protocols for managing interstitial lung disease in patients with systemic sclerosis to better identify high-risk subsets. AI Illustration. Upload story photo >

Live Poll

Do you trust that current medical research is making sufficient progress in treating autoimmune lung diseases?

Rheumatologists recently evaluated updated management guidelines for interstitial lung disease, a condition affecting up to 90% of systemic sclerosis patients. Clinicians focused on identifying the 15% to 20% of patients most likely to experience disease progression.

Why it matters

Identifying specific patient subsets prone to rapid disease progression is essential for optimizing treatment outcomes. Early intervention with established therapies remains the primary strategy for managing lung-related systemic sclerosis complications.

Clinical guidelines highlight that patients diagnosed for fewer than 5 years face a higher risk for disease progression. Treatment options are largely centered on mycophenolate mofetil as a first-line therapy, with rituximab utilized for cases involving skin disease.

The players

Congress of Clinical Rheumatology West

This is a professional medical event where specialists gather to discuss the latest advancements and protocols in the field of rheumatology.

The details

Specialists screen patients using baseline pulmonary function tests and CT scans to monitor for interstitial lung disease. Treatment paradigms are then adjusted based on a patient's individual manifestations of skin, muscle, or joint disease, particularly for those with low forced vital capacity or extensive fibrosis.

October 2, 2026: Experts discussed current treatment guidelines at the Congress of Clinical Rheumatology West.

The Big Picture

This assessment of clinical care standards aligns with findings from the FIBRONEER-ILD study, which showed nerandomilast improved forced vital capacity. Such research continues to expand the therapeutic landscape for patients suffering from systemic sclerosis-related lung disease.

Patients with systemic sclerosis should consult their rheumatologist about regular pulmonary function testing to monitor for early signs of lung disease. These updated treatment pathways emphasize the importance of early detection and personalized care plans tailored to individual symptom profiles.

The takeaway

Patients who have had systemic sclerosis for less than five years or exhibit extensive fibrosis on scans should work closely with their doctors to monitor for progression. Proactive screening and adherence to first-line therapies are critical steps in preserving lung function and managing this complex condition.